New Jersey 2024-2025 Regular Session

New Jersey Assembly Bill A4023

Introduced
3/7/24  

Caption

Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

Impact

The bill mandates the creation and maintenance of a prioritization list of prescription drugs, devices, and biological products for bulk purchasing initiatives. This list will help focus state efforts on high-cost items that represent significant expenditures. The prioritization criteria include the drug's price, availability of alternatives, and past purchase costs to the State, aiming to enhance financial efficiency in healthcare spending across state programs and agencies. Furthermore, local governments and private purchasers will have the opportunity to benefit from these arrangements, promoting broader access to essential healthcare products.

Summary

Assembly Bill A4023 aims to establish requirements for State entities in New Jersey to enter into bulk purchasing arrangements for pharmaceutical products. The bill is designed to maximize the State's bargaining power with regard to the procurement of pharmaceuticals and pharmacy services, thereby reducing costs associated with purchasing these essential products. The Director of the Division of Purchase and Property in the Department of Treasury will oversee this initiative, reviewing all current contracts and arrangements to identify opportunities for cost savings through collective purchasing efforts.

Contention

Notable points of contention surrounding A4023 may arise from concerns about the implications for competition in the pharmaceutical market and potential pushback from drug manufacturers. Supporters argue that consolidating purchasing power can lower costs and enhance access to medications, particularly for state-run programs. Critics, however, may contend that such measures could undermine market dynamics and innovation or pose challenges for smaller suppliers who might struggle to compete in a bulk purchasing framework. Transparency in the prioritization process and ongoing evaluations of the program's effectiveness will be needed to address these concerns.

Companion Bills

NJ S1396

Same As Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

NJ S781

Carry Over Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

Previously Filed As

NJ A3106

Establishes requirements for State to enter into contract for purchase of menstrual products.

NJ A1797

Authorizes State and local law enforcement entities to contract for bulk purchasing of heroin antidote.

NJ HB3613

Relating to pharmaceutical purchasing; prescribing an effective date.

NJ SB1553

Authorizes incentives for producing certain critical materials and pharmaceuticals

NJ S1583

To restore integrity in the marketing of pharmaceutical products and medical devices

NJ SB154

Prohibit pharmaceutical manufacturers from interfering in contracts between 340B entities and pharmacies and to provide a penalty therefor.

NJ HB07179

An Act Concerning Pharmaceutical Marketing And Pharmaceuticals.

NJ HB88

Health Insurance – Bulk Purchasing Pools for Prescription Drugs

NJ HB0088

Health Insurance – Bulk Purchasing Pools for Prescription Drugs

NJ HB4392

Banning certain dyes from pharmaceutical products

Similar Bills

CA AB2588

District agricultural associations: board of directors: vacancies.

CA AB1225

State parks: Accessibility Advisory Committee.

CA AB929

An act to amend Section 10721 of, and to amend, repeal, and add Sections 10726.

CA AB1198

Public works: prevailing wages.

TX HB2014

Relating to the election of the board of directors of the Somervell County Hospital District.

CA AB1141

An act to amend Sections 24801, 24826, 24827, 24830, 24862, and 24908 of, to repeal Section 24861 of, and to repeal and add Section 24863 of, the Public Utilities Code, relating to transportation.

CA SB975

Nursing schools and programs: faculty members, directors, and assistant directors.

CA AB1870

Private Attorneys General Act: penalties: reduction.